Most patients “won’t see benefit” with Alzheimer’s drugs

Pharmaphorum

A review of clinical data on amyloid-targeting Alzheimer’s therapies has found absent or trivial efficacy, but is facing pushback from some experts.

Policy / PricingNeuroscienceRead full story